Precision BioSciences up as hepatitis B gene‑editing trial expands in Europe

Precision Biosciences

15/04/2026 12:14

** Precision BioSciences DTIL.O shares rise 2.35% to $7.40 premarket

** Biotech firm says it won approval to add France and Romania to its ELIMINATE‑B study of PBGENE‑HBV, an experimental treatment for chronic hepatitis B

** Adds that expansion aims to speed up patient enrolment in Europe, adding to existing sites in the UK, the U.S., and Asia-Pacific

** Chronic hepatitis B has no cure, and the drug is designed to target the root cause of the long-term liver infection, with the aim of a one‑time, curative treatment - DTIL

** Adds that site preparation has begun, with initial patient screening expected in Q2 2026

** Co's PBGENE‑HBV has FDA Fast Track status

** As of last close, stock up ~74% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))